NCT06381271 Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation
| NCT ID | NCT06381271 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Aortic Valve Regurgitation |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2018-10-30 |
| Primary Completion | 2034-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2018-10-30 with a primary completion date of 2034-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected
Eligibility Criteria
Inclusion Criteria: * 1\. Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy. * 2\. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form Exclusion Criteria: * 1\. Patients who cannot provide informed consent * 2\. Patients who are treated with TAVR for aortic stenosis * 3\. Patients who are participating in other clinical trials
Contact & Investigator
Ling Tao, M.D, Ph.D
STUDY CHAIR
Xijing Hospital
Frequently Asked Questions
Who can join the NCT06381271 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aortic Valve Regurgitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06381271 currently recruiting?
Yes, NCT06381271 is actively recruiting participants. Contact the research team at rutaowang@qq.com for enrollment information.
Where is the NCT06381271 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06381271 clinical trial?
NCT06381271 is sponsored by Xijing Hospital. The principal investigator is Ling Tao, M.D, Ph.D at Xijing Hospital. The trial plans to enroll 500 participants.